Epidemiology and Biomarker Study in Alzheimer's Disease
About this study
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Condition
- Alzheimer Disease
- Tested
- P-tau217 Test
- Sponsor
- Eli Lilly and Company
Who can join
- Age
- 55 to 75 years
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 5
- Minimum age: 55 years
- Maximum age: 75 years
- Study condition: Alzheimer Disease
- The participant must self-report unimpaired cognition.
- The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.
Exclusion 4
- Have seen a doctor about memory concerns.
- Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
- Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
- Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.
Where
4 sites, 4 recruiting
The University of Tokyo Hospital
Bunkyō City, Japan
Souseikai Sumida Hospital
Tokyo, Japan
Higashi Shinjuku Clinic
Tokyo, Japan
Care Access - Houston
Houston, Texas, United States
Contact
-
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559 LillyTrials@Lilly.com
-
Physicians interested in becoming principal investigators please contact
Potential match only. Final eligibility is determined by the study team.